Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
Change of CD20 expression was examined in cases of diffuse large B-cell lymphoma (DLBCL). CD20 expression after treatment with anti-CD20 antibody (rituximab, Rx) for DLBCL was examined in 23 cases who received serial biopsy by immunohistochemistry (IHC) and flow cytometry (FCM). CD20– by IHC and/or...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2009-10-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/249152 |
| _version_ | 1818621610432659456 |
|---|---|
| author | Naoki Wada Masaharu Kohara Hiroyasu Ogawa Haruo Sugiyama Shirou Fukuhara Yoichi Tatsumi Akihisa Kanamaru Masayuki Hino Yuzuru Kanakura Eiichi Morii Katsuyuki Aozasa |
| author_facet | Naoki Wada Masaharu Kohara Hiroyasu Ogawa Haruo Sugiyama Shirou Fukuhara Yoichi Tatsumi Akihisa Kanamaru Masayuki Hino Yuzuru Kanakura Eiichi Morii Katsuyuki Aozasa |
| author_sort | Naoki Wada |
| collection | DOAJ |
| description | Change of CD20 expression was examined in cases of diffuse large B-cell lymphoma (DLBCL). CD20 expression after treatment with anti-CD20 antibody (rituximab, Rx) for DLBCL was examined in 23 cases who received serial biopsy by immunohistochemistry (IHC) and flow cytometry (FCM). CD20– by IHC and/or FCM was defined as CD20–. Four cases were CD20– at initial biopsy but became CD20+ after chemotherapy with Rx (CH-R) (group A). Recurrent tumors in three group A cases became resistant to CH-R. Initial and recurrent tumors were CD20+ before and after CH-R in 17 cases (group B). Tumors before CH-R were CD20– in two cases (group C) and continued to be CD20– in one and turned CD20+ in the other with survival time after the relapse of 8 and 23 months, respectively. Evaluation of CD20 expression with immunohistochemical and flow cytometric methods is used for the prediction of responsiveness of relapsed DLBCL for CH-R. |
| first_indexed | 2024-12-16T18:12:01Z |
| format | Article |
| id | doaj.art-9c5599a221f14eb3b126dc4ef9e90113 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-16T18:12:01Z |
| publishDate | 2009-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-9c5599a221f14eb3b126dc4ef9e901132022-12-21T22:21:45ZengKarger PublishersCase Reports in Oncology1662-65752009-10-012319420210.1159/000249152249152Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study GroupNaoki WadaMasaharu KoharaHiroyasu OgawaHaruo SugiyamaShirou FukuharaYoichi TatsumiAkihisa KanamaruMasayuki HinoYuzuru KanakuraEiichi MoriiKatsuyuki AozasaChange of CD20 expression was examined in cases of diffuse large B-cell lymphoma (DLBCL). CD20 expression after treatment with anti-CD20 antibody (rituximab, Rx) for DLBCL was examined in 23 cases who received serial biopsy by immunohistochemistry (IHC) and flow cytometry (FCM). CD20– by IHC and/or FCM was defined as CD20–. Four cases were CD20– at initial biopsy but became CD20+ after chemotherapy with Rx (CH-R) (group A). Recurrent tumors in three group A cases became resistant to CH-R. Initial and recurrent tumors were CD20+ before and after CH-R in 17 cases (group B). Tumors before CH-R were CD20– in two cases (group C) and continued to be CD20– in one and turned CD20+ in the other with survival time after the relapse of 8 and 23 months, respectively. Evaluation of CD20 expression with immunohistochemical and flow cytometric methods is used for the prediction of responsiveness of relapsed DLBCL for CH-R.http://www.karger.com/Article/FullText/249152CD20RelapseDiffuse large B-cell lymphomaRituximabClonality |
| spellingShingle | Naoki Wada Masaharu Kohara Hiroyasu Ogawa Haruo Sugiyama Shirou Fukuhara Yoichi Tatsumi Akihisa Kanamaru Masayuki Hino Yuzuru Kanakura Eiichi Morii Katsuyuki Aozasa Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group Case Reports in Oncology CD20 Relapse Diffuse large B-cell lymphoma Rituximab Clonality |
| title | Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group |
| title_full | Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group |
| title_fullStr | Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group |
| title_full_unstemmed | Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group |
| title_short | Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group |
| title_sort | change of cd20 expression in diffuse large b cell lymphoma treated with rituximab an anti cd20 monoclonal antibody a study of the osaka lymphoma study group |
| topic | CD20 Relapse Diffuse large B-cell lymphoma Rituximab Clonality |
| url | http://www.karger.com/Article/FullText/249152 |
| work_keys_str_mv | AT naokiwada changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup AT masaharukohara changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup AT hiroyasuogawa changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup AT haruosugiyama changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup AT shiroufukuhara changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup AT yoichitatsumi changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup AT akihisakanamaru changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup AT masayukihino changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup AT yuzurukanakura changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup AT eiichimorii changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup AT katsuyukiaozasa changeofcd20expressionindiffuselargebcelllymphomatreatedwithrituximabananticd20monoclonalantibodyastudyoftheosakalymphomastudygroup |